Aldeyra Therapeutics (ALDX) Debt Ratio (2013 - 2026)

Aldeyra Therapeutics (ALDX) has reported Debt Ratio for 14 consecutive years, with 0.46 the latest figure, recorded in Q1 2026.

• For the quarter ending Q1 2026, Debt Ratio rose 181.31% year-over-year to 0.46; the trailing twelve-month figure through Mar 2026 stood at 0.46 (up 181.31% YoY), and the FY2025 full-year result was 0.42, up 192.14% from the prior year.
• Debt Ratio improved to 0.46 in Q1 2026 per ALDX's latest filing, from 0.42 in the prior quarter.
• Across five years, Debt Ratio topped out at 0.46 in Q1 2026 and bottomed at 0.07 in Q1 2022.
• Historically, Debt Ratio has averaged 0.2 across 5 years, with a median of 0.14 in 2022.
• The sharpest annual moves came in 2022 and 2025: Debt Ratio slumped 48.69% in 2022, then jumped 198.03% in 2025.
• Over 5 years, Debt Ratio stood at 0.09 in 2022, then soared by 131.57% to 0.2 in 2023, then declined by 29.3% to 0.14 in 2024, then jumped by 192.14% to 0.42 in 2025, then advanced by 8.57% to 0.46 in 2026.
• According to Business Quant data, Debt Ratio over the past three periods registered 0.46, 0.42, and 0.39 for Q1 2026, Q4 2025, and Q3 2025 respectively.